Antwerp (BE) / Marseille (FR) — In a Series B finan­cing round tota­ling $53 million, Gimv has increased its stake in ImCheck Thera­peu­tics, an emer­ging provi­der of onco­logy and auto­im­mune therapy solu­ti­ons based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new inves­tors. In addi­tion to Gimv, exis­ting inves­tors Life Scien­ces Part­ners (LSP), Idin­vest Part­ners, Kurma Part­ners and Boeh­rin­ger Ingel­heim Venture Fund also parti­ci­pa­ted to a signi­fi­cant extent in the increase.

The Series B round funds will be used to finance initial clini­cal trials of ImCheck Thera­peu­tics’ first-in-class mono­clonal anti­body ICT01. For exam­ple, the broad pipe­line of immu­no­mo­du­la­tors for the so-called buty­ro­phi­lin super­fa­mily will be further expan­ded and new anti­body thera­pies in the field of immuno-onco­­logy will be made available to clinics.

Bram Vanpa­rys, Part­ner at Gimv and respon­si­ble for the invest­ment on the Health & Care plat­form, says: “ImCheck has made signi­fi­cant progress since our invest­ment in the Series A round. As a result, we are plea­sed to have attrac­ted a number of new nota­ble inves­tors from the U.S. and Europe for the Series B round. Gimv’s signi­fi­cant invest­ment in this finan­cing round demons­tra­tes the poten­tial in ImCheck’s pipe­line of solu­ti­ons for the onco­logy and auto­im­mune therapy space.”

About GIMV
Gimv is a Euro­pean invest­ment company with almost 40 years of expe­ri­ence in private equity. The company is listed on Euron­ext Brussels, curr­ently mana­ges around EUR 1.2 billion and curr­ently invests in 50 port­fo­lio compa­nies, which toge­ther realize a turno­ver of more than EUR 2.5 billion and employ 14,000 people.

Gimv iden­ti­fies inno­va­tive, leading compa­nies with high growth poten­tial and supports them on their way to market leader­ship. Each of the four invest­ment plat­forms Connec­ted Consu­mer, Health & Care, Smart Indus­tries and Sustainable Cities is mana­ged by a dedi­ca­ted and compe­tent team, each based in Gimv’s home markets — Bene­lux, France and DACH — and supported by an exten­sive inter­na­tio­nal network of experts. www.gimv.com